Ocular Therapeutix, Inc. (OCUL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.43-9.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · OCUL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 52.1 | 52.0 | 63.7 | 58.4 | 51.5 | 43.5 | 17.4 | 4.2 | 2.0 | 1.9 | 1.9 | 1.8 | 0.8 |
| Total Revenues | — | — | — | — | — | — | — | — | 2.0 | 1.9 | 1.9 | 1.8 | 0.8 |
| Cost of Revenues | 6.7 | 6.6 | 5.6 | 5.3 | 4.5 | 4.4 | 2.1 | 2.3 | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 223.5 | 197.1 | 127.6 | 61.1 | 53.5 | 50.1 | 28.7 | 41.1 | 36.9 | 30.9 | 27.1 | 26.6 | 18.9 |
| Operating Income | (313.9) | (270.0) | (171.8) | (82.4) | (78.7) | (78.0) | (62.8) | (85.8) | (59.1) | (61.9) | (43.3) | (38.2) | (27.1) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 11.8 | 13.6 | 11.3 | 7.0 | 6.7 | 6.8 | 6.1 | 1.7 | 1.9 | 1.7 | 1.7 | 1.1 |
| Other Non-Operating Income / Expenses | 12.5 | 4.1 | (21.7) | 1.6 | 7.6 | 71.5 | (92.8) | (0.6) | (0.9) | (1.5) | (1.4) | (1.6) | (1.6) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||||
| Net Income | (301.4) | (265.9) | (193.5) | (80.7) | (71.0) | (6.6) | (155.6) | (86.4) | (60.0) | (63.4) | (44.7) | (39.7) | (28.6) |
| Per Share | |||||||||||||
| Basic EPS | (1.34) | (1.42) | (1.22) | (1.01) | (0.92) | (0.09) | (2.56) | — | — | — | — | — | — |
| Diluted EPS | (1.34) | (1.42) | (1.22) | (1.02) | (0.97) | (0.98) | (2.56) | — | — | — | — | — | — |
| Revenue per Share | 0.23 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 225.0 | 187.2 | 158.3 | 79.8 | 76.9 | 76.4 | 60.8 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 225.0 | 187.2 | 158.3 | 85.6 | 82.6 | 82.2 | 60.8 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (265.7) | (168.0) | (79.4) | (76.5) | (75.6) | (60.1) | (83.3) | (56.8) | (60.3) | (42.4) | (37.4) | (26.5) |
| EBIT | (313.9) | (270.0) | (171.8) | (82.4) | (78.7) | (78.0) | (62.8) | (85.8) | (59.1) | (61.9) | (43.3) | (38.2) | (27.1) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.